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Abstract
Background: Tuberculosis (TB) control is considered primarily a public health concern, and private sector TB treatment has
attracted less attention. Thus, the size and characteristics of private sector TB drug sales remain largely unknown.
Methodology/Principal Findings: We used IMS Health data to analyze private TB drug consumption in 10 high burden
countries (HBCs), after first mapping how well IMS data coverage overlapped with private markets. We defined private
markets as any channels not used or influenced by national TB programs. Private markets in four countries – Pakistan, the
Philippines, Indonesia and India – had the largest relative sales volumes; annually, they sold enough first line TB drugs to
provide 65–117% of the respective countries’ estimated annual incident cases with a standard 6–8 month regimen. First line
drug volumes in five countries were predominantly fixed dose combinations (FDCs), but predominantly loose drugs in the
other five. Across 10 countries, these drugs were available in 37 (loose drug) plus 74 (FDCs) distinct strengths. There were 54
distinct, significant first line manufacturers (range 2–11 per country), and most companies sold TB drugs in only a single
study country. FDC markets were, however, more concentrated, with 4 companies capturing 69% of FDC volume across the
ten countries. Among second line drugs, fluoroquinolones were widely available, with significant volumes used for TB in
India, Pakistan and Indonesia. However, certain WHO-recommended drugs were not available and in general there were
insufficient drug volumes to cover the majority of the expected burden of multidrug-resistant TB (MDR-TB).
Conclusions/Significance: Private TB drug markets in several HBCs are substantial, stable, and complicated. This calls for
appropriate policy and market responses, including expansion of Public-Private Mix (PPM) programs, greater reach,
flexibility and appeal of public programs, regulatory and quality enforcement, and expansion of public MDR-TB treatment
programs.
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Introduction
Tuberculosis (TB) remains a leading killer globally: despite
notable treatment successes, it is associated with 1.7 million deaths
every year [1], and there are more estimated cases each year based
on population growth. Approximately 80% of the global TB
burden is concentrated in 22 high burden countries (HBCs); 10 of
these HBCs, covering 60% of the global burden [1], are included
in this study. TB treatment has been considered primarily as a
public health priority, because lengthy, supervised treatment is
needed to maximize cure rates, reduce incidence, and minimize
the development of resistance. Indeed, in the 10 HBCs under
study here, 67% of estimated incident cases are at some stage
detected and treated by national TB programs [1]. A significant
amount of private sector TB treatment is, however, known to exist.
In the public sector, TB treatment policies are typically based
on World Health Organization (WHO) recommendations [2,3],
and for first line treatment most countries adhere to a 6 month
course denoted, in shorthand, as 2HRZE/4RH (2 months of
isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E),
followed by four months of isoniazid and rifampicin). Sales of
standard dosages by the Global Drug Facility (GDF) reinforce
these recommendations. For a given country, these treatment
policies are usually decided centrally and are uniformly applied.
Thus, estimating average treatment practices in the public sector is
easier than in the private sector, where decision making is made at
the healthcare provider or patient level.
We know, however, that private sector treatment is often in-
appropriate:inone studyinIndia,100privatedoctorsprescribed 80
different regimens [4], and a recent update showed no significant
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were reported to use inappropriate regimens 89% of the time [6]
and it is known that patients often run out of money and so cannot
complete treatment in the private sector [7]. The World Health
Organization (WHO) responded to these problems by introducing
the concept of public-private mix (PPM), which links the private
sector to public sector treatment norms [8,9]; PPM has also
benefited from use of the International Standards for Tuberculosis
Care (ISTC) [10]. Unfortunately, however, the expansion of PPM
in most settings has been relatively limited.
Studies of private sector behavior (as noted above) have
generally been limited to small, localized samples that reveal
diversity of practice but do not provide an overall sense of the
major trends. Basic questions such as the relative size of the private
market across HBCs, specific dosage strengths used, use of fixed
dose combinations (FDCs) or loose pills, and leading manufactur-
ers in this space have not been documented, despite the fact that
the private markets in HBCs are not new and continue to serve, in
certain countries, as major channels for treatment by patients. Our
current analysis of TB drug sales data provides this missing
overview of private market practices over time in a wide array of
geographies.
Even less is known about possible private sector treatment of
multidrug-resistant TB (MDR-TB). Despite an estimated burden
of 440,000 new MDR-TB cases per year [1], public sector
capacity for diagnosis and treatment is lagging: in 2008, only 7%
of the estimated cases were detected and reported and less than
one fifth of those reported cases were managed according to
international guidelines [11]. The private sector may be stepping
in to fill this gap, but data on this are lacking.
From a public health standpoint, understanding the private
market is critical to ultimately improving overall outcomes in TB.
In contrast to most National TB Programs (NTPs), the private
markets operate in a decentralized and largely unregulated
fashion, with few mechanisms in place to monitor and ensure
evidence-informed prescribing and patient adherence to a TB
regimen, creating risks for developing drug resistance [11]. To
better understand how change can be effected in this sector, the
global TB community first needs a baseline understanding of the
TB market.
In a previous study, we focused on sizing the global market for
TB drugs, including estimates of private TB drug market value for
five high burden countries (HBCs) [12,13]. Our new analysis
covers five additional HBCs and provides, for the first time, a
detailed definition and identification of private sector channels, the
types of products being sold, their volumes, sales trends and the
manufacturers producing these drugs. The results suggest a
diverse, sizable and stable private TB drug market that will
continue to affect treatment outcomes in both private and public
sectors.
Methods
IMS Health Inc. (IMS) tracks drug sales by recruiting various
data sources (manufacturers, wholesalers, distributors, hospitals,
pharmacies, other dispensing facilities, and healthcare providers),
who submit prescription and drug sales information. The data
collection strategy is different for each country based on the
structure of the health system and the data sources available (see
File S1), but in each case a set of channels (e.g., hospitals plus
pharmacies plus non-pharmacy distributors) is used to construct a
picture of the entire drug dispensing landscape. Results are
validated by cross-checking with manufacturer data on specific
products (see below).
Of the 22 high burden countries (HBCs) for drug-sensitive TB,
only 11 are covered by current IMS data collection efforts. One of
these 11 HBCs, Brazil, is thought to have no private market for TB
drugs. We therefore focused on the remaining 10 HBCs (listed by
2009 HBC rank [14]): India (1); China (2); Indonesia (3); South
Africa (5); Bangladesh (6); Pakistan (8); the Philippines (9); Russia
(11); Viet Nam (12) and Thailand (18). Based on the estimated
number of incident cases, these 10 countries include 60% of the
estimated burden of TB [1]. IMS data were not available for other
countries in sub-Saharan Africa including Nigeria (4), Ethiopia (7)
and DR Congo (10).
For each of the study countries, we defined the ‘‘private market’’
as those channels that are not used or influenced by national TB
programs (NTPs); this mirrors the revised definition for the scope
of PPM [9] and is in many cases similar to the retail market
considered, by drug companies, as distinct from the government
tender market [13]. Government-funded treatment for particular
sectors, such as the prisons, the military, or government railway
workers, were considered more likely to follow NTP guidelines and
thus were not included. In the remaining non-NTP channels,
however, physicians and other health care providers are not
obligated to comply with NTP guidelines or documentation
requirements, and patients are often, but not always, responsible
for treatment cost. Local IMS affiliates provided information on
the major drug distribution channels and outlets in each study
country; these channels were then classified as either (a) public
sector; (b) private sector with IMS audit; or (c) private sector
without IMS audit. Data were pulled from category (b) channels
(see File S1 for details). Of note, in some countries certain hospitals
are nominally public sector but have no link to the NTP (i.e., TB
drug prescribing by health workers, and TB drug purchasing by
both hospitals and patients, are independent of the NTP). For this
study, such outlets were, to the extent possible, included as ‘private
sector’ (see File S1).
In the channels defined as private, IMS coverage of outlets (i.e.,
number of outlets sampled divided by estimated total number of
these outlets) ranged from 1–20%, with the exception of .80%
coverage in South Africa and in one of the two relevant channels
in Pakistan. Sampling reliability was assessed via the ‘‘precision
index’’, which is the percentage of all products (i.e., not restricted
to TB drugs) for which the IMS prediction falls within +/222.5%
of manufacturer-supplied distribution (or sales) data. These
precision indices ranged from 64–66% (for 3 study countries) to
.80% (for the remaining 7 countries). In addition to this measure
of clustering, the bias (average under- or over-estimation, when
compared to manufacturer-reported figures) for these countries
averaged 213% (range 219% to +2%, with the exception of
Bangladesh (225%) and Vietnam (239%)).
In medical audits, a panel of 4,600 physicians (India) or 350–540
physicians (Indonesia, Pakistan, Philippines, South Africa, and
Thailand) were asked to note the indication associated with each
drug prescribing event over a period of one full week of prescribing.
The physicians involved were internists or general physicians (30–
50% of total), pulmonologists (2–5%) and other specialists. Such
audits were not available for the four remaining study countries.
For second line drugs, we analyzed the overall market and their
use specifically for TB. Volumes for TB were smaller relative to
volumes for other indications, so analysis of the medical audit was
more challenging. We only used medical audit data for which a
95% confidence interval was measurable and deviated ,=66%
above or below the reported figures; the remaining figures were
deemed unreliable.
For all countries, the drugs investigated were the four most
common first line drugs (rifampin (R), isoniazid (H), pyrazinamide
Private Sector TB Drug Usage
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current WHO recommendations for second line treatment [15],
and two additional fluoroquinolones (ciprofloxacin and gatiflox-
acin) that are not recommended but known to be used for TB.
Volume data were reported in standard units, representing a single
tablet, capsule, dose (for vials, ampoules or other liquid forms), or
sachet. Drugs sold were used as a proxy for drugs used, as
commercial considerations were expected to keep wastage to a
minimum. Sales data were converted to US dollars at the time of
data collection. Strengths were reported for .=92% of volume
for all except India (80%), South Africa (75%) and Bangladesh
(54%), with most missing strengths being from 3- and 4-drug fixed
dose combinations (FDCs).
Pricing data were adjusted for each country to the wholesaler
acquisition level, using conversion factors calculated either at a
margin mandated by the government (such as in South Africa) or
usingalargepool ofproducts(suchasinChina).Pricesfora firstline
regimen were calculated presuming a six month regimen anddosing
of 3.5 tablets (average of the two most common weight bands) of the
WHO-recommended 4-drug FDC RHZE (for 2 months) and 2-
drug FDC RH (for 4 months), or their single drug equivalents. The
same assumptions were used to convert first line drug volume data
into ‘‘months of treatment’’ after first adjusting for the volume that
had missing strengths. For the analogous calculation for fluoro-
quinolones, we assumed daily dosages of 800 mg (ofloxacin),
1000 mg (levofloxacin), or 400 mg (moxifloxacin or gatifloxacin),
or twice daily dosage of 500 mg (ciprofloxacin).
Ethical approval was not required for the study as it relied on
secondary data from a routine recording and reporting system.
Results
Alignment of IMS data channels with the private sector
As a first step in the analysis, we defined the ‘‘private sector’’ and
its alignment with IMS data channels. The private sector was
defined as encompassing all TB drugs that were being supplied
outside of the policy or prescribing influence of NTPs (regardless of
payer identity). This definition arguably made the most sense in
terms of both working with IMS’s data collection strategy (see
below) and maximizing the policy relevance of the data. For some
countries,thisdefinitionwassimple:itincludedthe retailmarket but
excluded the bulk government tenders (which are often missing
from IMS data anyway) [13], but for other countries the required
subdivision of IMS channels was more complex (see File S1).
We rejected alternative definitions of the ‘‘private sector’’ such
as ‘‘paid by private payer’’ or ‘‘supplied by for-profit provider’’.
IMS data do not include the identity of the drug payer (i.e.,
consumer, insurance company, or government), so measuring the
volume of TB drugs paid for by consumers was judged impossible,
at least with IMS data. Similarly, IMS data are not always sampled
at the provider level. However, in all countries we could map a
correspondence between certain IMS channels and our definition
of the private sector. This strategy also measures the sector of most
interest to policy makers: the channels that are outside of NTP
policy oversight and thus have the most uncertain prescribing
practices.
We evaluated three major areas of possible errors in aligning
IMS channels and the NTP-independent private sector. First, our
stated volumes could be underestimates as there are private sector
channels in which IMS does not collect data, and there are also
public sector channels that were excluded even though not all of
their outlets (e.g., public hospitals in Viet Nam) collaborate with
the relevant NTP. However, these missing channels were
estimated to account for 20% (China) or ,=12% (all other study
countries) of total pharmaceutical volume, based on comparisons
between manufacturer and IMS survey data in each country.
Second, the stated volumes could be an overestimate if NTP
influence ‘‘contaminates’’ the choice of TB drugs in what we
believe is the independent private sector. In China, for example,
certain ‘‘designated hospitals’’ have established a collaboration
with the NTP [16], although the extent may be limited as 150 of
the 189 designated hospitals (as of 2009) were concentrated in 4
provinces with 17% of the country’s population. Other PPM
initiatives are limited in size, and most would not register in our
analysis as they refer patients to the public sector for treatment
[17] or use drugs supplied by the public sector [18,19,20,21].
Finally, non-governmental organization (NGO) operations
should not complicate our analysis. We consider it unlikely that
a major NGO would be allowed to operate (by donors and
national partners) if their TB regimens did not align with national
and international norms; thus, NGO drugs should be omitted
from our definition of the (non-NTP-influenced) private sector.
This omission appears to happen in practice. In the study
countries, Me ´decins sans Frontie `res, for example, either has no TB
operations, or imports its drugs, procures via the public sector, or
places orders directly with manufacturers (Carine Werder, pers.
comm.). In Bangladesh, BRAC obtains TB drugs from the
national TB program, which purchases from GDF (Md Akramul
Islam, pers. comm.). None of these activities would be detected in
our analysis. The exception may be NGO MDR-TB programs,
some of which purchase second line drugs directly from the private
sector, but most of these programs remain limited in size.
Sizing of private, first line TB drug markets
Before considering first line drug volumes, we first checked the
medical audits. The percentage of first-line TB drugs used for TB
was .=94% in Indonesia, Philippines and Pakistan, .=89% in
Thailand, .=48% in South Africa (due primarily to classification
of TB/HIV under ‘‘HIV’’), and .=67% in India (due primarily
to additional sub-classifications of pulmonary disease not present
on the IMS forms used in other countries). The two exceptions
were for rifampicin in Pakistan (only 78% for TB, due mainly to
use for brucellosis) and India (46%). As many of the ‘‘non-TB’’
uses appeared to misclassification of TB as other diseases, we made
the simplifying assumption that all first line TB drugs in all 10
study countries were used for TB.
The ten study countries had private, first line TB drug markets
that were either large (India, Indonesia, the Philippines, and
Pakistan, with volumes of first line drugs sufficient to treat 65–117%
of the estimatednew TB casesinthosecountriesina given year with
a full, daily 6–8 month regimen), medium (China, Russia and
Thailand; 13–23%) or minimal (Bangladesh, South Africa and
Vietnam; 3–7%) (Table 1). As a simplifying assumption, and purely
for the purposes of illustration, we presumed that all patients
received a full, daily course of the six-eight month WHO-
recommended treatment regimen. Ethambutol usage was relatively
higher in India, Philippines, Pakistan, and China, with figures being
consistent with 20–40% of private sector usage involving 8 month
regimens (2HRZE/6EH) in these countries. Alternatively, many
other ethambutol-rich regimens may be in use. In total, private
sector first line TB drugs in these 10 countries are sufficient to treat
66% of the countries’ estimated incident cases, or 39% of the
estimated incident cases worldwide. For 2008–9, they represented
US$122 million of sales at wholesaler acquisition prices.
First line drug sales in the private market have been relatively
stable during the period we studied (2004–2009). Change over the
entire period was less than 10% in 5 HBCs; the exceptions were
China (+59%), Thailand (210%), Philippines (216%), Viet Nam
Private Sector TB Drug Usage
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market is from India alone (whereas India represents only 35% of
the 10-country overall TB burden); 85% is accounted for by India,
China and Indonesia.
FDC penetration of private markets
Each country’s private market has shown a clear preference
toward either FDCs or loose drugs: five countries predominantly
use FDCs in the private market (India, Pakistan, Philippines,
Bangladesh and South Africa have ,36% use of loose drugs) while
the other five countries typically use loose drugs (China, Indonesia,
Russia, Thailand and Vietnam have .=90% use of loose drugs)
(Table 1). From 2004–2009, the largest volume trend between
FDCs was a slight increase in the use of 4-drug FDCs (from 27%
to 32% of all FDCs). In the FDC-dominant countries, 3-drug
FDCs are either significant (26–37% of FDCs in India, Pakistan
and Philippines) or almost absent (0–4% in Bangladesh and South
Africa). Across all loose and FDC drugs, oral pills (tablets or
capsules) account for 94% of volume.
First line drugs are sold in a wide variety of strengths
For all four first-line drugs, a wide variety of strengths were sold.
Diversity of drug strengths was high for both loose drugs (7–22
distinct dosage strengths per country; 37 in total) and FDCs (2–48
dosage strengths per country; 74 in total) (Table 2). Diversity was
highest in India. Across all countries, non-standard strengths
(neither identical to nor in a multiple of GDF or NTP
recommendations) accounted for 35% of the volume of first line
drugs with a known strength (Figure 1). However, there is notable
clustering of the average strengths close to GDF-recommended
dosages, particularly for loose Z and E (Figure 2), and the most
popular 3- and 4-drug FDCs are at strengths sold by GDF. On
average, tablets sold in China are of lower strengths and tablets
sold in India are of higher strengths (Figure 2).
Private first line drug prices are usually higher than GDF’s
list price
Not surprisingly, the average drug cost in the private market is
often higher than the procurement prices listed by GDF (,US$25
per 6 month course), with wholesaler acquisition prices of loose
and/or FDC-based regimens over US$50 in Indonesia, Philip-
pines, Russia, South Africa, Thailand and Vietnam (Figure 3). The
lowest price was in China, which uses provincial level bidding for
both NTP and non-NTP facilities. In countries with relatively little
FDC use, the FDC-based regimens are significantly more
expensive than loose-drug-based regimens; this rule does not hold
in the other 5 countries.
The first line market is fragmented overall, but the FDC
market is more concentrated
There were 54 distinct first line manufacturers with .3%
market share in at least one country (range 2–11 per country).
Lupin, Wyeth and Sandoz are the only three of the top 12 first line
manufacturers that sell products in the private markets of more
than one study country: they cover two, two and eight of the study
countries, respectively. Thus, most of the private markets are
fragmented and include a large number of domestic manufactur-
ers. However the FDC market is relatively more concentrated than
the loose drug market, likely due to the challenges associated with
producing FDCs. As a result, the five countries where FDCs are
dominant have only 16 unique manufacturers with .3% total
share, compared to 40 across the remaining five countries. Figure 4
presents a country by country comparison.
The top 10 manufacturers of loose drugs account for 62% of the
10-country loose drug market. For FDCs, the top 10 and top 4
FDC manufacturers account for 87% and 69%, respectively, of
the FDC market. Three of the top four FDC manufacturers –
Lupin, Macleods and Sandoz – produce FDCs that are pre-
Table 1. Size and characteristics of private TB drug market.
Country
Incident
cases
(2008)
Coverage
by first line,
private sector
drugs*
% change
in volume
2004–9
% of private
market that
is loose drugs
Number of
manufacturers with
.3% of private first
line market share
Fluoroquinolone
coverage of
incident
MDR-TB cases
#
Fluoroquinolone
coverage of all
incident cases
&
India 1,982,628 117% 23% 23% 6 41% 6.1%
Indonesia‘ 429,730 116% 25% 91% 6 12% 1.0%
Philippines 257,317 86% 216% 16% 6
Pakistan 409,392 65% 27% 36% 4 13% 1.3%
China‘ 1,301,322 23% 59% 98% 9
Thailand‘ 92,087 17% 210% 94% 9
Russia‘ 150,898 13% 5% 100% 7
Vietnam‘ 174,593 7% 228% 90% 11
Bangladesh 359,671 7% 251% 11% 2
South Africa 476,732 3% 2% 34% 2
Weighted average 66% 5% 52%
Global Total 9,369,038
10 country total, as % of
global incidence
60% 39%
*% of all incident cases that can be treated by first line drugs in private market (average across 4 first line drugs, assuming daily 6–8 month regimen). Data for this and
other columns, unless noted, are for Q4 2008–Q3 2009.
‘Denotes countries in which .=90% of first line TB drugs in the private sector are loose.
#Assuming daily dosing for 18 month regimen, and no use for drug-sensitive TB.
&Assuming daily dosing for 6 month regimen, and no diagnosis of drug-resistant TB.
doi:10.1371/journal.pone.0018964.t001
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FDCs in the private markets in the study countries, only 7% of
that 56% is in dosage forms that are prequalified (and likely even
less would be from the prequalified manufacturing sites).
The 2nd line market across all indications lacks certain
drugs
The market volume for second line drugs (used for both TB and
non-TB indications) has been growing (at 5% or more per year)
and is dominated by India (63%) and China (17%). Most countries
lack any significant (.2000 standard units) private sector sales
volumes of capreomycin, clofazimine, and most of the oral
bacteriostatic agents (Table 3). On average, each of the ten
countries lack significant volume of 4.8 out of the 17 recom-
mended second line drugs (range 0–8), but seven of the countries
have at least one drug available in each of the categories. Volume
is, however, concentrated in certain drugs: across all indications,
fluoroquinolones and amoxicillin/clavulanate account for 96% of
volume of second line drugs (43% of the total is ciprofloxacin
alone); the only other drugs with .1% share are amikacin and
clarithromycin.
Fluoroquinolone volumes and coverage of the MDR-TB
burden
Six countries have medical audits, allowing assessment of second
line drug volumes used for TB. Across all second line drugs for TB
in these countries, India is even more dominant, accounting for
93.5% of the total volume (whereas India represents only 66% of
the estimated 6-country overall MDR-TB burden).
With certain drugs in certain countries, very small volumes for
TB rendered the medical audit unreliable. However, there were
three countries in which at least the three fluoroquinolones most
Figure 1. First line TB drug volumes broken down by strength, compared to GDF/NTP standards. First line drugs were classified as
having strengths identical to those purchased by the Global Drug Facility (GDF) or recommended by the relevant National TB Program (NTP), or
integer multiples of such strengths (e.g., twice as much or half as much). The remaining strengths (‘‘other’’; purple bars at top) constituted 35% of
total volume. (Note: only products with known strengths were used in the calculation.)
doi:10.1371/journal.pone.0018964.g001
Table 2. Number of strength forms used for FDCs and loose drugs.*
Country RH HE HZ RHE RHZ RHZE
Total FDC
dosages in
country R H Z E
Total loose
dosages in
country
India 15 2 8 15 8 48 527822
Philippines 7 4 3 3 2 19 652215
Pakistan 5 3 3 4 2 17 522211
Indonesia 3 6 1 1 11 543214
Bangladesh 5 4 1 10 32117
Vietnam 3 1 1 1 1 7 32117
South Africa 4 1 1 6 41117
Thailand 2 1 1 4 42129
Russia 1 1 1 1 4 43119
China 1 1 2 831113
10-country total 20 13 1 11 18 11 74 11 9 8 9 37
*Products with unknown strengths were not included in this analysis.
doi:10.1371/journal.pone.0018964.t002
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had measurable error margins after the medical audit. Actual
dosaging practices may vary but, for illustrative purposes, the
amount of measurable fluoroquinonolones used for TB could
supply the daily dosages for an entire 18-month WHO-
recommended MDR-TB treatment regimen for 54%, 15% or
11% of total estimated incident MDR-TB patients [22] in India,
Indonesia, and Pakistan, respectively. Alternatively, use of these
drugs as a daily addition to six month first line regimens (a non-
recommended but known practice) would result in coverage
of 6%, 1.3% and 1% of estimated incident drug-sensitive TB
patients. Ciprofloxacin, a fluoroquinolone not recommended for
TB [15], made up 29%, 38% and 38% of all measurable
fluoroquinolones for TB in these countries.
Extending our analysisbeyondthe fluoroquinolones,wenote that
second line drug usage for TB is concentrated among very few
drugs. In India, Indonesia, Pakistan and the Philippines, the four
countries with the largest drug volumes and most reliable medical
audits, fluoroquinolones and streptomycin account for 74% and
14%, respectively, of 2nd line volume for TB. (Both drugs were
counted here as second line drugs.) This leaves only 1% of volume
for the other, preferred injectables such as kanamycin, capreomycin
Figure 3. Prices of loose drug- and FDC-based 6 month regimens. Average prices per mg (for loose drugs) and for 4- and 2-drug FDCs (for
FDCs) were used to calculate the average cost of a daily, 6 month 2HRZE/4HR regimen.
doi:10.1371/journal.pone.0018964.g003
Figure 2. Strength variation for each first line drug. For each country and each active pharmaceutical ingredient (API), average strengths
(weighted according to volume) were calculated and compared to those purchased by GDF.
doi:10.1371/journal.pone.0018964.g002
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conclude that the percentage of the MDR-TB burden covered by
complete, rational MDR-TB regimens from the private sector is
likely to be small, with even an optimistic estimate being ,8-fold
lower than the fluoroquinolone numbers cited above.
Discussion
Private markets are an important part of the TB treatment
landscape. This study represents, to our knowledge, the first
detailed overview of the private TB drug market across countries
with the majority of the world’s TB burden. Whereas our previous
market study focused on capturing all TB drug value, regardless of
source, we now place an emphasis on defining the private sector
and providing an analysis of its characteristics in terms of both
products and manufacturers.
Based on the data in this study, the private TB drug market is
stable, sizable in several HBCs, and demonstrates extensive
variation in drug manufacturing and utilization patterns. The
variation in first line dosage strengths and the low volumes or lack
of availability of a number of second line agents suggest that both
first line and second line treatment in the private sector diverge
significantly from international and national guidelines. This,
combined with the previous evidence of variable and incomplete
treatment in the private sector, raises a considerable risk of
treatment failure and the development of drug resistance, and
strengthens the evidence supporting bold action in engaging the
private sector.
In the study countries, the number of incident TB patients
treated in public programs [14] and the number potentially
treated with private sector drugs (based on this study) are similar
(67% and 66% of incident cases, respectively). In a recent survey
[3], TB stakeholders provided estimates of private market size in
the 22 HBCs [23]. The relative ranking between countries from
this exercise was similar to that from the IMS drug usage data.
However, based on the IMS data, the absolute private market sizes
are substantially greater than those estimated by stakeholders,
likely due to repeated treatments in private and public sectors (and
possibly unrecognized burdens of TB and treatment of pneumonia
with TB drugs). The large size of certain private first line TB drug
markets is consistent with some previous reports, e.g., that in India
86% of patients first sought help in the private sector [24], and
that private practitioners provide overly lengthy regimens [5].
Private market size has remained stable despite the efforts by
NTPs in many countries to increase their share of the TB
treatment burden, and despite some indications that patient
perceptions of public sector TB treatment are changing [7]. This
suggests that the non-NTP providers in several HBCs are fulfilling
a continued need in the eyes of consumers, who choose to use the
private market even though free products are available through
their respective NTPs.
A variety of steps can be taken to prevent or limit irrational TB
drug dispensing in the private sector [11]. Regulations can be used
to restrict TB medications to the public sector (e.g., in Brazil); even
in this scenario, an efficient referral system is needed to reduce
diagnostic delays for patients first accessing the private sector. Of
note, our data show private sector TB drug volumes even in a
country (Russia) thought by stakeholders to have only public sector
TB drugs [23].
In countries with existing private TB drug markets, or for TB
drugs that have other major indications (e.g., fluoroquinolones), a
strictly regulatory approach may not be realistic. Other interven-
tions are possible, however. Public sector programs can be made
more extensive, appealing and flexible to reduce consumers’
private sector preference [25], and innovative and strengthened
PPM collaboration can be used to bring public sector treatment
norms to private sector providers. The size of these responses
should reflect the scale of the problem as identified here.
Figure 4. Number of manufacturers with first line FDC or loose drug market share greater than 3% (by volume, 2008–2009).
Compared to countries with predominantly FDCs, countries with predominantly loose drugs have more manufacturers with .3% first line market
share of either loose drugs (40 vs 17) or all first line drugs (40 vs 16). Numbers in figure legend are not a simple summation of numbers in figure as
some companies are present in multiple countries.
doi:10.1371/journal.pone.0018964.g004
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e18964For PPM, subsidized drugs appear to be an important
component for success in many settings [18,26], although some
interventions concentrate primarily on advocacy around treatment
norms [27]; of note, the impact of this latter intervention would
not be visible in our data. Increasing implementation of the
International Standards for Tuberculosis Care (ISTC) [10] via
professional associations, with a greater emphasis (or a special
campaign) on the standard regimens and dosages recommended,
could also help make private TB treatment more rational.
One reason for concern about the private market is the
variation in dosing practices, which has been documented
previously at the provider level [4,5,6]. With our data, we cannot
determine exact prescribing behaviors or the rationale behind
those behaviors, but we have obtained a comprehensive view of
the large numbers of dosages available to providers. With the
option of daily or intermittent dosing, the use of weight bands, an
old and incomplete evidence base, and variable practices between
countries, it becomes challenging to distinguish rational from non-
rational use. Even with standardized regimens, dosage errors can
be common [28], and dosage profusion only raises the likelihood
that private providers may make mistakes or that their patients will
be confused. Thus, the private sector is keeping alive the confusion
that existed previously in the public sector. Just as WHO and the
GDF helped to rationalize dosing in the public sector [29], so
regulators may be able to use market authorization to rationalize
private markets. Some guidance from WHO on this issue, geared
specifically to an audience of national regulatory authorities,
would seem appropriate. Manufacturers may also be persuaded
via provider demand to make only the strengths recommended by
WHO or the NTPs.
The fragmentation of the global TB drug market has been
noted previously [12]. We found, however, that such fragmenta-
tion is less pronounced in the FDC market, probably because
FDCs are newer and more challenging to manufacture. Action at
just four manufacturers (Lupin, Macleods, Wyeth and Sandoz) –
e.g., to limit production to rational dosages made with high quality
assurance – could reduce drug quality concerns for 69% of the
private sector FDCs in these 10 countries. In addition,
manufacturers could promote more uniformity of treatment via
standardization of information in package inserts and roll-out of
better provider educational materials.
In countries where FDCs have come to dominate the private
sector, their prices have fallen to equal or even undercut the prices
for loose drugs, an important learning for countries considering a
public sector switch to FDCs. Indeed, the number of manufac-
turers is sufficient to create competition in both FDC and loose
drug markets, and this competition may encourage manufacturers
to differentiate their products by creating large numbers of
strength variants. Confirmation of this hypothesis would require
manufacturer interviews.
Others have noted the poor availability of certain second line
drugs, notably capreomycin and clofazimine, despite their relative
desirability within their respective classes of MDR-TB drugs [30].
Our data on second-line drugs, though incomplete, are consistent
with these statements. Several WHO-recommended drugs are not
sold, and fluoroquinolones (and, to a lesser extent, streptomycin)
dominate the landscape. Thus, it would be challenging for private
providers to construct a full MDR-TB regimen in the private
sector, even if they had the requisite training and laboratory
facilities. However, the presence of many second line drugs
suggests that drug supplies may be available for possible scale-up
of MDR-TB treatment, either in the public or private sector.
In the largest private TB drug market, India, all second line
drugs are available, and volumes may expand greatly when rapid
point-of-care tests such as GeneXpertH MTB/Rif are scaled up in
the private sector.
Significant fluoroquinolone usage for TB does exist in several
countries, although given the much smaller volumes of other
second line agents, the fluoroquinolones are likely being used as
monotherapy or as an add-on to first-line therapy rather than as
part of a designated second-line therapy. (Based on the past history
of TB regimens, private providers may also consider streptomycin,
even more than fluoroquinolones, as a first line drug.) Thus, it
seems that most MDR-TB patients are not receiving sufficient
MDR-TB treatment in either the public [22] or private sector; the
vast majority of the estimated 440,000 new MDR-TB cases each
year [1] are likely not diagnosed or treated with rational MDR-TB
regimens. The limited private sector usage of most second line
drugs may be slowing the emergence of additional second line
drug resistance, although the finding of significant fluoroquinolone
usage for both TB and non-TB indications is consistent with the
increasing incidence of fluoroquinolone-resistant TB in certain
countries [31]. As the demand for both fluoroquinolones and other
second line drugs expands in the private sector, regulatory and
oversight approaches will become all the more important to
protect both lives and drugs.
A secondary goal of this study was to evaluate the robustness of
IMS data coverage for the TB drug markets in HBCs. IMS
databases are a commercial product, and sampling is conducted if
and when the effort and cost required can be supported by the
commercial value of the resulting data. As a result, data coverage
is incomplete in lower income markets. These limitations include a
complete lack of sampling (in 11 of the HBCs), less complete
sampling than in higher income countries (for the remaining 11
HBCs), no medical audit (in 4 of the remaining HBCs), smaller
medical audits, and certain additional data gaps.
Not surprisingly, IMS coverage is relatively low in the covered
HBCs (sampling 1–20% of all outlets, compared to 72% of
wholesalers in the USA or 94% of hospital beds in the UK, for
example). However, comparison with manufacturer data indicates
an acceptable level of accuracy (see Methods). Certain channels are
missed completely but relatively minor (see Results and File S1).
Medical audits, when available, proved reliable for first line
drugs due to large volumes and few alternative indications.
However, they were insufficient to provide reliable TB usage
estimates for a number of the second line drugs in countries with
less private sector TB treatment. For example, in some countries
data on the usage of fluoroquinolones for TB was swamped by
their usage for other indications, often in other formulations.
Every effort was made to exclude any private sector channels
that were under the influence of the relevant NTP, and any
challenges were judged to be manageable (see Results and File S1).
We also considered that data collection may be biased away from
outlets that serve lower income areas and clients, thus leading to
an under-estimate of TB drug volume. (The reverse bias is also
possible but arguably less likely.) This issue is a greater concern
when measuring TB drug consumption because of the extreme
concentration of TB in low income communities. It was not
possible to evaluate this possibility, or its potential impact,
although we note that IMS data in large countries are collected
independently in multiple regions to minimize geographical bias.
In the future, it may be worth embedding a simple, one-off income
or poverty survey in the IMS data collection mechanism to
determine whether any anti-poor bias exists.
On balance, these data issues suggest that under-estimation is
more likely than overestimation, and that the major conclusions
of this study are not likely to be affected by any of the data
uncertainties. IMS is increasing efforts to strengthen data collection
Private Sector TB Drug Usage
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sample size in rural areas, where many TB patients are treated in
the private sector, may continue to be limited. For many other
HBCs, a lack of financial incentive for IMS, combined with the
complexity of the various supply chains, may continue to be a
barrier to data-strengthening efforts. A recent public-private
partnership between the Medicines for Malaria Venture (MMV)
and IMS is now, however, seeking to fill this gap in Sub-Saharan
Africa (Renia Coghlan, pers. comm.).
Conclusion
The 10 HBCs varied significantly in the size of their private
markets for TB drugs. Particularly large and stable private sectors
for first line drugs were present in 4 HBCs, where carefully
documented public sector treatment numbers may obscure the
amount of private sector treatment occurring beforehand. In
considering interventions to address private sector TB treatment,
the size of the response should be commensurate with the size of
the problem. Greater government and international support for
implementing PPM, expanding the reach of public programs,
improving regulatory oversight for both marketing approvals and
quality assurance, and expanding public sector MDR-TB
diagnosis and treatment could have a great impact in strength-
ening TB treatment outcomes in the entire health sector.
Supporting Information
File S1 The supporting information describes the major TB
drug channels in each study country, the channels audited by IMS,
and how the IMS audit and private drug channels overlap.
(DOC)
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